Phoenix Pharmacologics, Inc.

Polaris Group

Phoenix Pharmacologies, Inc.

Mike A Clark

Charles Mark Ensor

Frederick Wayne Holtsberg

Modifying TNF with polyethyleneglycol (PEG) having an approximate weight average molecular weight in the range of about 10,000 to about 40,000, preferably in the range of about 20,000 to 30,000, significantly increases the circulating half-life of the TNF while not increasing its toxicity. As a result, lower doses of the TNF may be administered to effectively treat tumors with fewer, accompanying adverse side effects to the patient.

Modified tumor necrosis factor

The present invention is directed to arginine deiminase modified with polyethylene glycol, to methods of treating cancer, and to methods of treating and/or inhibiting metastasis.

Method of treatment with modified arginine deiminase

The present invention is directed to methods of modulating viral replication in vivo comprising administering to an individual a therapeutically or prophylactically effective amount of a composition comprising arginine deiminase modified with polyethylene glycol, to methods of concurrently modulating viral replication and treating cancer, and to methods of modulating nitric oxide levels in a patient, among others.

Methods for inhibiting viral replication in vivo

The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.

PEG-modified uricase

Modified arginine deiminase

The present invention provides novel expression systems for producing desired polypeptides in certain strains of yeast. The present invention further provides methods for producing polypeptide products using such expression systems. The present invention also provides compositions relating to the same.

Yeast expression systems, methods of producing polypeptides in yeast, and compositions relating to same

The present invention discloses arginine deiminase that is genetically modified for more efficient manufacturing and processing. The present invention discloses recombinant DNA molecules and vectors and other therapeutic and pharmaceutical compositions. The present invention also discloses methods for preparing modified arginine deiminase as well as methods of treating cancer and other disease states using modified arginine deiminase.

Growing community of inventors

Lexington, KY, United States of America

Mike A Clark